Celldex has announced the appointment of Teri Lawver as senior vice president, chief commercial officer.
Lawver is an accomplished global health care executive with 30 years of strategic, commercial launch and operating P&L leadership across the biopharmaceutical, medical device and consumer health technology sectors. She succeeds Richard Wright, who will retire from Celldex following more than a decade of dedicated leadership and service.
Lawver brings extensive experience in immunology and inflammation, having overseen multiple first-in-class portfolio advances and blockbuster launches, including pivotal indications for REMICADE (infliximab), STELARA (ustekinumab) and TREMFYA (guselkumab).
“We are thrilled to welcome Teri to the Celldex leadership team,” said Anthony Marucci, co-founder, president and chief executive officer of Celldex. “Teri brings an extraordinary record of success across global biopharmaceutical and medical technology companies. Her deep experience in immunology and inflammation, and track record in building and scaling commercial organizations will be invaluable as we prepare for the potential launch of barzolvolimab and advance our broader pipeline.
“I also want to sincerely thank Rick for his exceptional contributions over the past 10 years. His leadership and commitment have been instrumental in positioning Celldex for our next phase of growth, and we wish him all the best in his retirement.”
Before joining Celldex, Lawver was principal and owner of Thera Lifescience Advisors, where she was a strategic advisor to CEOs and investors at pioneering life science and health technology companies. Previously, she was chief commercial officer at Dexcom, Inc., where she was responsible for $4 billion in annual revenue and 1,900 employees across 50 countries.
Before that, Lawver was an executive at Johnson & Johnson, where she led significant and diverse global business units over her 20-year tenure, culminating as worldwide vice president for Janssen Immunology. She joined J&J through Centocor, where she was responsible for launching the industry’s first biologic therapies in the gastroenterology space.
Lawver currently serves on the board of directors of Altimmune, Inc. She holds a B.S. in linguistics from Georgetown University and an M.B.A. from Duke University’s Fuqua School of Business.
“I am thrilled to join Celldex at such a pivotal time in the company’s evolution,” said Lawver. “The company’s leadership in advancing mast cell biology and the team’s commitment to transforming outcomes for patients with severe allergic and inflammatory diseases are truly exciting.
“I look forward to contributing to Celldex’s mission and working alongside this talented team to bring the potential of these important therapies to patients in need.”
